Public Joint-Stock Company "Pharmsynthez" (LIFE.ME)

RUB 4.22

(1.2%)

Market Cap (In RUB)

1.27 Billion

Revenue (In RUB)

379.67 Million

Net Income (In RUB)

-207.49 Million

Avg. Volume

7.45 Million

Currency
RUB
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
3.905-4.9
PE
-1.819
EPS
-2.32
Beta Value
-0.05
ISIN
RU000A0JR514
CUSIP
X25768106
CIK
-
Shares
301011000.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Petr Vladimirovich Kurglyakov
Employee Count
-
Website
https://www.pharmsynthez.com
Ipo Date
2010-11-25
Details
Public Joint-Stock Company ‘Pharmsynthez', a pharmaceutical company, researches, manufactures, and distributes officinal and generic active pharmaceutical ingredients in Russia and CIS countries. The company offers officinal medicines, including Neovir, Segidrin, Fenasid, and Penkrofton that are used in oncology, gynecology, treatment of immune deficiencies, and tuberculosis. Public Joint-Stock Company ‘Pharmsynthez' has partnership with HiFiBiO Therapeutics Inks for the clinical development and commercialization of its SARS-CoV-2 neutralizing antibody in Russia. Public Joint-Stock Company ‘Pharmsynthez' was founded in 1996 and is based in St. Petersburg, Russia.